文献速递临床微生物质量管理与危急值

头孢吡肟-恩美唑巴坦肉汤微量稀释MIC与纸片扩散法药敏试验质控范围的建立

Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
PubMed 文献 · J Clin Microbiol · 2019-07-26

本研究采用CLSI M23二级研究设计,为头孢吡肟与新型β-内酰胺酶抑制剂恩美唑巴坦组合确定肉汤微量稀释MIC和纸片扩散法的质控范围。使用5株参考菌株,恩美唑巴坦固定浓度8 μg/ml,纸片含量30/20 μg。MIC质控范围覆盖3-4个倍比稀释度,包含99.6%-100.0%的测定值;纸片扩散抑菌圈直径质控范围跨度7 mm,涵盖97.1%-100.0%的测定值。质控范围已获CLSI批准。

要点

  • 恩美唑巴坦固定浓度8 μg/ml用于MIC测定,纸片扩散法使用30/20 μg纸片。
  • 产CTX-M-15的E. coli NCTC 13353推荐用于常规测试以控制ESBL抑制。
  • MIC质控范围覆盖3-4个倍比稀释度,包含99.6%-100.0%的测定值。

核心结论

  • 建立的质控范围可确保使用CLSI参考方法测定临床分离株对头孢吡肟-恩美唑巴坦的敏感性时达到适当的检测性能标准。

研究设计与样本

  • 采用CLSI M23二级研究设计,使用5株参考菌株(E. coli ATCC 25922、E. coli ATCC 35218、E. coli NCTC 13353、K. pneumoniae ATCC 700603、P. aeruginosa ATCC 27853)确定肉汤微量稀释MIC和纸片扩散法的质控范围。

主要发现

  • 肉汤微量稀释MIC质控范围覆盖3至4个倍比稀释度,包含99.6%至100.0%的五个参考菌株的测定MIC值。
  • 纸片扩散法抑菌圈直径质控范围跨度7 mm,涵盖97.1%至100.0%的测定值。

关键数值与推荐

  • 恩美唑巴坦在MIC测定中固定浓度为8 μg/ml。
  • 纸片扩散法使用头孢吡肟-恩美唑巴坦纸片含量30/20 μg。
  • 产CTX-M-15的E. coli NCTC 13353推荐用于常规测试以控制恩美唑巴坦对ESBL活性的抑制。
  • 质控范围经CLSI于2017年(肉汤微量稀释MIC)和2019年(纸片扩散)批准。

临床怎么用

  • 临床微生物实验室可采用本质控范围,使用CLSI参考方法对头孢吡肟-恩美唑巴坦进行药敏试验质控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Third-generation cephalosporin resistance among Enterobacteriaceae, mediated by the spread of extended-spectrum β-lactamases (ESBLs), is a very serious medical concern with limited therapeutic options. Enmetazobactam (formerly AAI101) is a novel penicillanic sulfone β-lactamase inhibitor active against a wide range of ESBLs. The combination of enmetazobactam and cefepime has entered phase 3 development in patients with complicated urinary tract infections. Using the Clinical and Laboratory Standards Institute (CLSI) M23 tier 2 study design, broth microdilution MIC and disk diffusion quality control (QC) ranges were determined for cefepime-enmetazobactam. Enmetazobactam was tested at a fixed concentration of 8 μg/ml in the MIC assay, and a cefepime-enmetazobactam disk mass of 30/20 μg was used in the disk diffusion assay. Escherichia coli ATCC 25922, E. coli ATCC 35218, E. coli NCTC 13353, Klebsiella pneumoniae ATCC 700603, and Pseudomonas aeruginosa ATCC 27853 were chosen as reference strains. The CTX-M-15-producing E. coli NCTC 13353 isolate is recommended for routine testing to control for inhibition of ESBL activity by enmetazobactam. Broth microdilution MIC QC ranges spanned 3 to 4 doubling dilutions and contained 99.6% to 100.0% of obtained MIC values for the five reference strains. Disk diffusion yielded inhibition zone diameter QC ranges that spanned 7 mm and encompassed 97.1% to 100.0% of the obtained values. Quality control ranges were approved by the CLSI in 2017 (broth microdilution MIC) and 2019 (disk diffusion). The established QC ranges will ensure that appropriate assay performance criteria are attained using CLSI reference methodology when determining the susceptibility of clinical isolates to cefepime-enmetazobactam.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Belley A, Huband MD, Fedler KA, et al. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam. J Clin Microbiol. 2019. PMID: 31167844. doi:10.1128/JCM.00607-19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。